Achillion (ACHN) Enters 6.4M Direct Offering at $6.57/Share
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Join SI Premium – FREE
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced today that it has entered into a definitive agreement with funds managed by QVT Financial LP for the sale of 6,367,853 shares of its common stock.
The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in gross proceeds to Achillion, before deducting estimated offering expenses, of approximately $41.8 million. The sale and issuance of the shares is expected to close on or about September 4, 2012, subject to customary closing conditions.
The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in gross proceeds to Achillion, before deducting estimated offering expenses, of approximately $41.8 million. The sale and issuance of the shares is expected to close on or about September 4, 2012, subject to customary closing conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China SXT Pharmaceuticals (SXTC) files for 157.5M share offering by selling stockholders
- Viking Acquisition Corp. II raises $230 million in NYSE IPO
- Expion360 COO resigns effective August 2026
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
QVT FinancialSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
